American Journal of Kidney Diseases
Volume 53, Issue 2 , Pages 259-272 , February 2009

Interventions for Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura: A Systematic Review of Randomized Controlled Trials

  • Mini Michael, MBBS, FRACP, MM(Clin Epi)

      Affiliations

    • Renal Section/Department of Pediatrics, Texas Children's Hospital/Baylor College of Medicine, Houston, TX
    • Corresponding Author InformationAddress correspondence to Mini Michael, MBBS, FRACP, MM(Clin Epi), Renal Section/Department of Pediatrics, Baylor College of Medicine, 6621 Fannin St, MC 3-2482, Houston, TX 77030
    • ,
  • Elizabeth J. Elliott, MBBS, MD, FRACP

      Affiliations

    • Discipline of Paediatrics and Child Health, University of Sydney, Sydney, Australia
    • Centre for Evidence Based Paediatric Gastroenterology and Nutrition, Cochrane Renal Group, The Children's Hospital at Westmead, Sydney, Australia
    • Australian Paediatric Surveillance Unit, Cochrane Renal Group, The Children's Hospital at Westmead, Sydney, Australia
    • ,
  • Jonathan C. Craig, MBChB, FRACP, PhD, MM(Clin Epi)

      Affiliations

    • Centre for Kidney Research, Cochrane Renal Group, The Children's Hospital at Westmead, Sydney, Australia
    • School of Public Health, University of Sydney, Sydney, Australia
    • ,
  • Greta Ridley, PhD

      Affiliations

    • Australian Paediatric Surveillance Unit, Cochrane Renal Group, The Children's Hospital at Westmead, Sydney, Australia
    • ,
  • Elisabeth M. Hodson, MBBS, FRACP

      Affiliations

    • Centre for Kidney Research, Cochrane Renal Group, The Children's Hospital at Westmead, Sydney, Australia

Received 25 February 2008 ,Accepted 30 July 2008.

References 

  1. Kaplan BS. Thrombotic microangiopathy: A proposal for a new terminology for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. J Nephrol. 1995;8:3–4
  2. Hosler GA, Cusanamo AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. Arch Pathol Lab Med. 2003;127:834–839
  3. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–1584
  4. Tsai H-M, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594
  5. Bianchi V, Robles R, Alberio L, et al. von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: A severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100:710–713
  6. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States—Analysis of national mortality data, 1968-1991. Am J Hematol. 1995;50:84–90
  7. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: All patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3:1432–1436
  8. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of literature. Medicine (Baltimore). 1966;45:139–159
  9. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60–68
  10. Allford SL, Hunt BJ, Rose P, Machin SJ. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology: Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120:556–573
  11. Byrnes JJ, Khurana H. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med. 1977;297:1386–1389
  12. Bukowski RM, Hewlett JS, Harris JW. Exchange transfusion in the treatment of thrombotic thrombocytopenic purpura. Semin Hematol. 1976;13:219–232
  13. Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Br J Haematol. 1996;94:383–386
  14. Sacher R, Moake J. Solvent detergent-treated plasma versus fresh frozen plasma in patients with TTP. Transfusion. 1996;36(suppl 95):63S
  15. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60:831–846
  16. Remuzzi G. The hemolytic uremic syndrome. Kidney Int. 1995;47:2–19
  17. Kaplan BS, Kaplan P. Hemolytic uremic syndrome in families. In:  Kaplan BS,  Trompeter R,  Moake J editor. Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York, NY: Marcel-Netter; 1992;p. 213–225
  18. Taylor CM. Hemolytic uremic syndrome and complement factor H deficiency: Clinical aspects. Semin Thromb Haemost. 2001;27:185–190
  19. Elliott EJ, Robins-Browne RM, O'Loughlin EV, et al. Nationwide study of haemolytic uraemic syndrome: Clinical microbiological, and epidemiological features. Arch Dis Child. 2001;85:125–131
  20. Rowe PC, Orrbine E, Wells GA, McLaine PN. Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988 (The Canadian Pediatric Kidney Disease Reference Centre). J Pediatr. 1991;119:218–224
  21. Milford DV, Taylor CM, Gutteridge B, Hall SM, Rowe B, Kleanthous H. Haemolytic uraemic syndromes in the British Isles 1985-8: Association with verocytotoxin producing Escherichia coli (Part 1: Clinical and epidemiological aspects). Arch Dis Child. 1990;65:716–721
  22. Martin DL, MacDonald KL, White KE, Soler JT, Osterholm MT. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med. 1990;323:1161–1167
  23. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: A systematic review, meta-analysis, and meta-regression. JAMA. 2003;290:1360–1370
  24. Decludt B, Bouvet P, Mariani-Kurkdjian P, et al. Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. Epidemiol Infect. 2000;124:215–220
  25. Neuhaus T, Calonder S, Leumann E. Heterogeneity of atypical haemolytic uraemic syndromes. Arch Dis Child. 1997;76:518–521
  26. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309:1286–1291
  27. Hollis S, Cambell F. What is meant by intention to treat analysis? (Survey of published randomised controlled trials). BMJ. 1999;319:670–674
  28. Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998;352:609–613
  29. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. JAMA. 1995;301:1410–1412
  30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  31. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP) (Results of a randomised multicenter trial by the Italian Cooperative Group for TTP). Haematologica. 1997;82:429–435
  32. Henon P. Thrombotic thrombocytopenic purpura: Clinical results of a French controlled trial. Transfus Sci. 1992;13:63–72
  33. Loirat C, Beaufils E, Sonsino N, et al. Treatment of haemolytic uraemic syndrome in children with urokinase. Arch Fr Pediatr. 1984;41:15–19
  34. Loriat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J. Treatment of the childhood haemolytic uraemic syndrome with plasma (A multicentre randomized controlled trial. The French Society of Paediatric Nephrology). Pediatr Nephrol. 1988;2:279–285
  35. Perez N, Spizzirri F, Rahman R, Suarez A, Larrubia C, Lasarte P. Steroids in hemolytic uremic syndrome. Pediatr Nephrol. 1998;12:101–104
  36. Rizzoni G, Claris-Appiani A, Edefonti A, et al. Plasma infusion for hemolytic-uremic syndrome in children: Results of a multicenter controlled trial. J Paediatr. 1988;112:284–290
  37. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325:393–397
  38. Rock G, Anderson D, Clark W, et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? (No answer yet). Br J Haematol. 2005;129:79–86
  39. Rothele E, Krumme B, Rump LC. Design of the prospective randomised study for the treatment of patients with thrombotic microangiopathy. Ther Apher. 2000;4:327–331
  40. Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhoea-associated haemolytic uraemic syndrome in children; A randomised controlled trial. JAMA. 2003;290:1337–1344
  41. Van Damme-Lombaerts R, Proesmans W, Van Damme B, et al. Heparin plus dipyridamole in childhood hemolytic-uraemic syndrome: A prospective randomized study. J Pediatr. 1988;113:913–918
  42. Vitacco M, Sanchez Avalos J, Gianantonio CA. Heparin therapy in the haemolytic uraemic syndrome. J Pediatr. 1973;83:271–275
  43. Zeigler ZR, Shadduck RK, Gryn JF, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic prupura (TTP). J Clin Apher. 2001;16:19–22
  44. Muller-Wiefel DE, Bulla M, Klare B, Balzar R, Bambauer R, Tonshoff B. Efficacy of therapeutic plasma exchange in haemolytic uraemic syndrome in childhood (abstracts, European Dialysis and Transplant Association-European Renal Association XXVIth Annual Congress, Göteborg, Sweden, 11-15 June 1989). Nephrol Dial Transplant. 1989;4:446A;(abstr)
  45. Thomson PD, Milnor LS: A randomly selected trial of vitamin E in the haemolytic uraemic syndrome (HUS). Proceedings of Xth International Congress of Nephrology 98 (Abstracts), London, July 26-31, 1987
  46. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927–1935
  47. Durand JM, Lefevre P, Kaplanski G, et al. Vincristine for TTP. Lancet. 1992;340:977–978
  48. Udvardy M, Rak K. Cyclophosphamide for chronic relapsing TTP. Lancet. 1990;336:1508–1509
  49. Crowther MA, Heddle N, Hayward CP, et al. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med. 1996;125:294–296
  50. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient TTP: A study of 11 cases. Blood. 2005;105:1932–1937
  51. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for TTP: A proposed study of the Transfusion Medicine/Hemostatsis Clinical Trials Network with a systematic review of rituximab therapy for immune mediated disorders. J Clin Apher. 2006;21:49–56
  52. Maxvold N, Bunchman TE. Renal failure and renal replacement therapy. Crit Care Clin. 2003;19:563–575

 Originally published online as doi:10.1053/j.ajkd.2008.07.038 on October 28, 2008.

PII: S0272-6386(08)01240-7

doi: 10.1053/j.ajkd.2008.07.038

American Journal of Kidney Diseases
Volume 53, Issue 2 , Pages 259-272 , February 2009

Article Tools

* Image Usage & Resolution